Gene-modified coxsackievirus

1. A modified coxsackievirus of which proliferation is suppressed in a tissue-specific manner, which comprises a mutated genome corresponding to genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of a tissue-specific microRNA (miRNA),

wherein the inserted polynucleotide is the polynucleotide of the following sequence of (a) or (b):

(a)

ATA CAT ACT TCT TTA CAT TCC Acg atA TAC ATA

CTT CTT TAC ATT CCA acc ggt TCC AAT CAG TTC

CTG ATG CAG TAt cac TCC AAT CAG TTC CTG ATG

CAG TA which is SEQ ID NO: 1; or

(b)

TCC AAT CAG TTC CTG ATG CAG TAc gat TCC AAT

CAG TTC CTG ATG CAG TAa ccg gtT CCA ATC AGT

TCC TGA TGC AGT Atc acT CCA ATC AGT TCC TGA

TGC AGT A which is SEQ ID NO: 2.

2. The modified coxsackievirus according to claim 1 , wherein the insertion position is in the 3′ UTR region of the CVB3-WT genome.

3. The modified coxsackievirus according to claim 1 , wherein the insertion position is a position upstream from the position 7344 or downstream from the position between the positions 7304 and 7305 of the CVB3-WT genome.

4. The modified coxsackievirus according to claim 1 , wherein the tissue-specific miRNA is one expressed in pancreas and/or myocardium.

5. The modified coxsackievirus according to claim 1 , wherein the tissue-specific miRNA consists of miR-1 and/or miR-217.

6. The modified coxsackievirus according to claim 1 , wherein 2 to 6 of the polynucleotides consisting of the target sequence are inserted.

7. The modified coxsackievirus according to claim 1 , wherein a region encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) is further inserted in an expressible form into the mutated genome.

8. The modified coxsackievirus according to claim 1 , wherein a polynucleotide containing a region encoding GM-CSF and a region encoding a 2A protease recognition sequence ligated downstream is further functionally inserted into the mutated genome at a position downstream from ATG of the translation initiation point and upstream from VP4 region.

9. The modified coxsackievirus according to claim 8 , wherein the 2A protease recognition sequence is a sequence modified so as to be recognizable by 2A protease derived from poliovirus.

10. The modified coxsackievirus according to claim 1 , which has a mutated genome comprising CVB3-WT genome inserted with a region encoding GM-CSF in an expressible form.

11. The modified coxsackievirus according to claim 1 , which has a mutated genome comprising CVB3-WT genome functionally inserted with a polynucleotide containing a region encoding GM-CSF and a region encoding a 2A protease recognition sequence ligated downstream at a position downstream from ATG of the translation initiation point and upstream from VP4 region.

12. The modified coxsackievirus according to claim 11 , wherein the 2A protease recognition sequence is a sequence modified so as to be recognizable by 2A protease derived from poliovirus.

13. A pharmaceutical composition containing the modified coxsackievirus according to claim 1 .

14. The pharmaceutical composition according to claim 13 , which is for prophylactic or therapeutic treatment of a lung cancer or a precancerous state thereof.

15. The modified coxsackievirus according to claim 1 for use in a prophylactic or therapeutic treatment of a lung cancer or a precancerous state thereof.

16. A method for a treatment of a lung cancer or a precancerous state thereof: the method comprising administering the modified coxsackievirus according to claim 1 to a subject in need of treating the lung cancer.

17. The pharmaceutical composition according to claim 13 , which is a preparation for topical application or systemic administration.